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Humans do not synthesize chitin, yet they produce a number of active and inactive chitinases. One
of the active enzymes is chitotriosidase whose serum levels are elevated in a number of diseases
such as Gaucher’s disease and upon fungal infection. Since the biological role of chitotriosidase in
disease pathogenesis is not understood we screened a panel of mammalian GlcNAc-containing gly-
coconjugates as alternate substrates. LacNAc and LacdiNAc-terminating substrates are hydrolyzed,
the latter with a turnover comparable to that of pNP-chitotriose. Glycolipids or glycoproteins with
LacNAc and LacdiNAc represent potential chitinase substrates and the subsequent alteration of gly-
cosylation pattern could be a factor in disease pathogenesis.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved1. Introduction
Chitin, a linear polymer of b1,4 linked N-acetylglucosamine
(GlcNAc) is found in insects, crustaceans and most fungi, but not
in plants, vertebrates or prokaryotes. Chitinases that hydrolyze chi-
tin are ubiquitous enzymes produced by a wide variety of organ-
isms, including some that do not contact or produce chitin [1].
These include humans which produce two catalytically active
chitinases, chitotriosidase (CHIT1) and acidic mammalian chitinase
(AMCase) and four catalytically inactive chitinase-like proteins or
chitolectins with mutations in the putative active site [2–5]. Hu-
man chitinases and chitolectins are all members of CAZy glycosidehydrolase family 18 [6]. The catalytically active enzymes CHIT1
and AMCase are both 50 kDa proteins, comprised of a 39 kDa cat-
alytic region and C-terminal CBM 14 chitin binding module [3,7].
CHIT1 is produced in mature macrophages, neutrophils, Gau-
cher’s cells and lung macrophages [4,5,7] and CHIT1 plasma levels
are elevated in pathological conditions including Gauchers disease
where it is secreted as the active full-length 50 kDa form [8]. An ac-
tive proteolyzed 39 kDa form is found in lysosomes. The biological
basis for the roles of chitotriosidase in human disease remains un-
clear since no cellular targets have been identiﬁed. In this study we
survey a panel of GlcNAc containing glycoconjugates as alternate
substrates for CHIT1. The structures are ﬂuorescently labelled con-
jugates to facilitate screening and they contain terminal LacNAc
(Galb1-4GlcNAc), LacdiNAc (GalNAcb1-4GlcNAc) or Type 1
(Galb1-3GlcNAc) motifs (Fig. 1 and Supplementary Fig. 1). Several
of these conjugates were hydrolyzed including LacdiNAc at a com-
parable rate to that of pNP-chitotriose. Hydrolysis of cellular glyco-
conjugates with these terminal structures might be associated
with chitotriosidase pathologies.
Fig. 1. Fluorescent substrates used in this study. Their exact structures are shown in Supplementary Fig. 1.
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2.1. Production of CHIT1 in HEK293 EBNA cells
Full-length CHIT1 cDNA (BC105682) for the 50 kDa form of en-
zyme was cloned into the StrepII C-term vector pCPR0051 (pCEP4-
CTStrepII) and the construct veriﬁed by sequencing. After transfor-
mation into Mach1-T1 cells (Invitrogen) DNA was puriﬁed using
the Nucleobond PC 10000 EF kit (Macherey–Nagel). Cells were
grown in unsupplemented Freestyle 293 expression medium, and
incubated in an orbital shaker incubator at 37 C, 70% humidity,
5% CO2 and 120 rpm (Ø50 mm). 1 day prior to transfection,
HEK293 EBNA cells were re-suspended in fresh media to a cell den-
sity of 1.2  106 cells/mL and incubated overnight. Approximately
15 min before transfection, cells were harvested, re-suspended to
50 mL in fresh media at a cell density of 20  106 cells/mL and
incubated until transfection. 2500 lg DNA (50 lg/mL ﬁnal) and
5 mL of polyethylenimine ‘‘MAX’’ (PEI) (Polysciences) (100 lg/mL
solution ﬁnal) was added directly to the cell suspension. 4 h post
transfection, 950 mL of media was added to a ﬁnal volume of 1 L
of cell suspension.
Five days post transfection the supernatants were collected by
centrifugation at 6500 rpm for 10 min at 4 C. After addition of 2
tablets of cOMPLETE protease inhibitor (Roche), the supernatants
were stored at 80 C.
2.2. Puriﬁcation
CHIT1 was puriﬁed using Strep-tag/Strep-Tactin puriﬁcation
system (IBA Technologies). Prior to the puriﬁcation the superna-
tant was concentrated by 65% ammonium sulfate precipitation or
was supplemented with 2 units of biotin decoy solution, Avadin
(IBA) and 10% buffer W (IBA) to adjust to pH 7 (untreated superna-
tant). Precipitated protein dissolved in 50 mL buffer W (pH 7) or
untreated supernatant (240–300 mL) was loaded onto a 5 mL
Strep-Tactin superﬂow H-PR cartridge (IBA, 2-1232-001) at a ﬂow
rate of 1–1.5 mL/min using a peristaltic pump. Washing and elu-
tion of protein was performed according to the manufacturer’s
instructions. Fractions containing protein were pooled followed
by concentration and exchanged into 50 mM sodium phosphate
buffer with Vivaspin (30000 Da cutoff, GE Healthcare). The protein
concentration was determined by the Bradford method using a
commercial kit (Bio-Rad) with bovine c-globulin as a protein
reference.2.3. Examination of enzyme activity towards chitin and cellulose
pseudo-substrates
The activity of CHIT1 was determined using the chitin pseudo-
substrates; 4-nitrophenyl N-acetyl-b-D-glucosaminide (pNP-Glc-
NAc), 4-nitrophenyl-N,N0-diacetyl-b-D-chitobioside (pNP-(Glc-
NAc)2), 4-nitrophenyl-N,N0,N0 0-triacetyl-b-D-chitotriose (pNP-
(GlcNAc)3) and the cellulose pseudo-substrate 4-nitrophenyl-b-D-
cellobioside (pNP-cellobioside) with a commercial chitinase kit
(Sigma). In a standard assay 5 lL enzyme diluted in 50 mM sodium
phosphate buffer, pH 6.0, and 45 lL 1 mg/mL substrate dissolved in
50 mM sodium phosphate buffer, pH 6.0 were incubated at 30 C.
Samples (50 lL) were removed after 30 min to 24 h and the reac-
tion was quenched by adding 250 lL of sodium carbonate (0.4 M,
pH 11). To limit the conversion of substrates to a maximum of
15%, the enzyme was diluted to 111 lg/mL in the pNP-(GlcNAc)2
assay and pNP-(GlcNAc)3 assay. Absorbance was measured in a
plate reader at 405 nm and corrected for absorption in a control
sample with added sodium phosphate buffer, pH 6.0, instead of en-
zyme. Absorption values were converted into concentrations by
the use of a p-nitrophenol (Sigma) standard curve.
2.4. Examination of CHIT1 with LacNAc-TMR, LacdiNAc-TMR,
Type1-TMR and GlcNAc-TMR substrates
The ﬂuorescently labeled substrates had a tetramethylrhod-
amine (TMR) tag covalently linked to carbohydrates via a hydro-
phobic linker (Fig. 1 and Supplementary Fig. 1). Their preparation
has been described previously [10,11]. 2 lL of the respective sub-
strates, GlcNAcb-O-(CH2)8CONH(CH2)2NHCO-TMR (GlcNAc-TMR)
(1.5 mM), Gal-b1,4-GlcNAc-O-(CH2)8CONH(CH2)2NHCO-TMR (Lac-
NAc-TMR) (1.9 mM), GalNAc-b1,4-GlcNAc- O-(CH2)8CONH(CH2)2-
NHCO-TMR (LacdiNAc-TMR) (1.9 mM), or Gal-b1,3-GlcNAc-O-
(CH2)8CONH(CH2)2NHCO-TMR (Type 1-TMR) (1 mM) were incu-
bated with 4 lL of enzyme (CHIT1 68 lg/mL) at room temperature
for 30 min to 20 h. Reaction progress was monitored by removing
0.5 lL aliquots for thin-layer chromatography on silica gel plates
developed with CHCl3/MeOH/H2O (65/35/5). TMR-labeled com-
pounds have a bright red color and thus are visible by eye. When
appropriate, supernatants from cells lacking expression of CHIT1
were used as a negative control.
Kinetic parameters for LacNAc-TMR and LacdiNAc-TMR were
determined by monitoring product formation with 8 different con-
centrations of substrate ranging from 0.015 to 0.80 mM (LacNAc-
Table 1
Summary of CHIT1 catalytic activities.
Substratea Chitotriosidase
pNP-assay pNP-GlcNAc 
pNP-(GlcNAc)2 +*
pNP-(GlcNAc)3 +
pNP-cellobioside 
TLC-assay GlcNAc-TMR 
Type I-TMR 
LacdiNAc-TMR +
LacNAc-TMR +
For pNP-assay: +: positive reaction (ABS405 > 0.08), : negative reaction
(ABS405 < 0.08). For TLC-assay: +: bright red spot visible to the eye, : no spot
visible to the eye.
* Apparent decrease in enzyme activity with increasing substrate concentration
due to transglycosylation.
a pNP-GlcNAc: 4-nitrophenyl-N-acetyl-b-D-glucosaminide, pNP-(GlcNAc)2: 4-
nitrophenyl-N,N0-diacetyl- b-D-chitobioside, pNP-(GlcNAc)3: 4-nitrophenyl-b-D-
N,N0 ,N0 0-triacetylchitotriose, pNP-cellobioside: 4-nitrophenyl-b-D-cellobioside.
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electrophoresis [12]. The reaction volume was 10 lL in 50 mM so-
dium phosphate buffer, pH 6.0 and enzyme concentrations were 3–
45 lg/mL. Aliquots (1 lL) were removed at 15–60 min and
quenched with 50 lL of CE running buffer (50 mM borate, pH
9.3, and 150 mM sodium dodecyl sulfate). Analyses were per-
formed on an automated PrinCE 560 CE system from PrinCE Tech-
nologies B.V. (Emmen, The Netherlands). Separations were carried
out in an uncoated fused-silica capillary of 75 lm i.d. with CE run-
ning buffer. TMR-labeled compounds were detected and quanti-
tated using an Argos 250B ﬂuorescence detector (Flux
Instruments) equipped with an excitation ﬁlter of 546.1/10 nm
and an emission ﬁlter of 570 nm. All experiments were carried
out at a normal polarity, i.e. inlet anodic. Data were processed with
PrinCE 7.0 software.
2.5. Examination of CHIT1 activity with LacNAcb1-60LacNAc,
LacNAcb1-6Galb1-3-GalNAc and LacNAcb1-2-Man-(sp)(Gly)Thr(Gly)
monitored by UPLC–MS
For derivatization, oligosaccharides were dissolved in PBS
(pH8.5) at 50 lM (LacNacb1-60LacNAc and extended core 2
[13,14] or 100 lM (LacNAc-Man, [15]). TMR-N-hydroxy-
succinimide ester (3 equiv., 3 lL in DMSO) was added to each oli-
gosaccharide solution [LacNAcb1-60LacNAc: 15 lL (750 nmol),
Extended Core 2: 10 lL (500 nmol) or LacNAc-Man (20 lL
(2000 nmol)] (Supplementary Fig. 2). The reaction mixture was
covered with foil to prevent exposure to light and was incubated
overnight at room temperature. The derivatized product was puri-
ﬁed by binding and elution from a C18 Sep-Pak cartridge (Waters,
Milford, MA) and by silica TLC [solvent system: CHCl3/MeOH/
water (65:35:5)].
Enzyme reactions consisted of TMR-labeled compound
(1.25 lM), CHIT1 (1 lg), 25 mM sodium phosphate buffer, pH 6.0,
in a total volume of 4 lL. After incubation for 18 h at room temper-
ature, the reaction mixture was diluted with 300 lL of 10 mM
ammonium formate, pH 4.5 (22%)/acetonitrile (88%) (v/v) for
UPLC–MS analysis.
UPLC–MS analysis was performed on a Waters Acquity UPLC–
MS system with ﬂuorescence detection (kex = 540 nm; kem = 580 -
nm) using a Waters Acquity UPLC GST Amide Column (1.7 mm,
2.1  150 mm). Buffer A (10 mM ammonium formate, pH 4.5)
and B (acetonitrile) were used. The mobile phase ﬂow rate was
set at 0.2 mL/min, with elution starting at 20% buffer A and 80%
buffer B, followed by a linear gradient to 40% buffer B in 15 min.
The eluted peaks were identiﬁed with a coupled mass spectrome-
ter, Waters Micromass Quattro Premier Tandem quadrupole mass
spectrometer. The instrument was operated using an electrospray
source in positive mode. The ionization source conditions wereFig. 2. Hydrolysis of pNP-(GlcNAc)2 and pNP-(GlcNAc)3. 111 lg/mL CHITas follows: capillary voltage of 4 kV, source block temperature of
120 C and solvent evaporation temperature of 250 C. The cone
voltage was 10–50 V. The data acquisition and processing were
performed using MassLynx V4.1 software (Micromass, Manchester,
UK).
3. Results
3.1. CHITI activity with chitin and cellulose pseudo-substrates
Human CHIT1 were obtained from HEK293 EBNA cells with
23.4 mg of puriﬁed protein obtained per liter of supernatant (Sup-
plementary Fig. 3). CHIT1 activity was evaluated with a panel of
chitin and cellulose pseudo-substrates and hydrolyzed pNP-(Glc-
NAc)2 and pNP-(GlcNAc)3 but not pNP-GlcNAc or pNP-cellobioside.
In agreement with the literature [9], a decrease in reaction rate was
observed at high substrate concentrations of pNP-(GlcNAc)2 attrib-
uted to transglycosylation (Fig. 2). The turnover number for pNP-
(GlcNAc)2 before the reduction of activity by transglycosylation is
1.5 s1. For pNP-(GlcNAc)3 a turnover of 0.5 s1 was obtained for
saturating substrate with a Km of 95 ± 25 lM (Fig. 2).
3.2. CHITI activity with LacNAc-TMR and LacdiNAc-TMR
Activity was tested towards the mammalian model substrates
LacNAc-TMR, Type I-TMR and LacdiNAc-TMR (Table 1). CHIT1
was active with both LacdiNAc-TMR and LacNAc-TMR as moni-
tored by TLC (Fig. 3 and Table 1). Complete hydrolysis of LacdiN-
Ac-TMR to the linking arm occurred within 30 min, while only a1 was incubated with the respective substrates for 30 min at 30 C.
Fig. 3. TLC of reaction mixtures incubated for (A) 30 min and (B) 3 h reactions with CHIT1. The TMR-labeled compounds have a bright red color and thus are visible by eye.
From the left, the TMR-labeled substrates were GlcNAc-TMR, Type 1-TMR, LacNAc-TMR, LacdiNAc-TMR. The fast moving spot at the top corresponds to Linker-TMR
demonstrating that LacdiNAc and LacNAc are removed from the linker as disaccharides. The rate of hydrolysis of LacdiNAc-TMR is considerably more rapid than LacNAc-TMR.
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There was no GlcNAc-TMR intermediate detected by TLC, thus
disaccharides are hydrolyzed from the linker. CHIT1 did not hydro-
lyze the isomeric Type I-TMR or GlcNAc-TMR. The kinetics with
both substrates was also examined by capillary electrophoresis.
The turnover for LacNAc-TMR was 0.003 ± 0.0002 s1 with a Km
of 34 ± 6 lM and with rates decreasing at concentrations above
500 lM (Supplementary Fig. 4). This highly unusual proﬁle was
reproducible and is attributed in part to competition between sub-
strate hydrolysis and transglycosylation. The kcat for LacdiNAc-TMR
was 0.40 ± 0.01 s1, with a Km of 57 ± 7 lMwith rates decreasing at
concentrations above 400 lM (Fig. 4). The kcat for LacdiNAc-TMR is
comparable to that for pNP-(GlcNAc)3.
3.3. CHITI activity with larger oligosaccharides LacNAcb1,6LacNAc-
TMR and extended core 2-TMR
Larger oligosaccharides terminating in LacNAc were only avail-
able in small amounts thus UPLC–MS was used to monitor their
enzymatic conversions. LacNAcb1,6LacNAc-TMR was converted to
LacNAc-TMR disaccharide (40%) and the TMR linker (59%) in over-
night incubations demonstrating that disaccharide units were
sequentially removed by CHIT1 (Fig. 5). Only a small amount (less
than 0.2%) of the extended Core 2-TMR was converted to Core 1-
TMR (Galb1, 3GalNAc-TMR). Larger concentrations of enzyme0 100 200 300
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Fig. 4. Kinetics of LacdiNAc-TMR hydrolysis by CHIT1 (0.3 pmol). The hydrolysis
product (Linker-TMR) was monitored by capillary electrophoresis. Substrate
inhibition was observed above 400 lM substrate.and longer incubation times did not increase the amount of con-
version of extended Core2-TMR. LacNAcb1, 2Man-TMR was not a
substrate for the enzyme (Fig. 5).
4. Discussion
We examined a panel of GlcNAc-containing disaccharides and
oligosaccharides as potential substrates for human CHIT1. The
full-length 50 kDa recombinant enzyme produced in HEK293 EBNA
cells exhibited substrate inhibition at higher concentrations of
pNP-(GlcNAc)2 attributed to transglycosylation as reported in the
literature [9]. Turnover before substrate inhibition was 1.5 s1.
For pNP-(GlcNAc)3 a turnover of 0.5 s1 was obtained giving a ratio
for chitobioside/chitotrioside activity of 3. This is in agreement
with the ratios of 3.9 and 3 obtained for the truncated 39 kDa
and 29 kDa chitotriosidases [2]. It has also been shown that 4-
methylumbelliferyl-(40 0-deoxy) chitobiose which lacks the hydro-
xyl group at C-4 of the non-reducing GlcNAc is a better substrate
for CHIT1 than 4-methylumbelliferyl-chitobiose (4MU-(GlcNAc)2)
(9). The deoxy-analog has a Km of 50 lM and 4–5-fold greater
activity than 4MU-(GlcNAc)2, in part due to the inability to under-
go transglycosylation. This also suggests that CHIT1 has some lat-
itude with respect to recognition of the terminal 4-OH in
substrates. Thus we examined LacdiNAc-TMR, which is the 40 0-epi-
mer of chitobiose as a potential substrate. While hydrolases can
have strict speciﬁcity for a given epimer, LacdiNAc was cleaved
by CHIT1. The turnover of LacdiNAc-TMR substrate was 0.4 s1
which is comparable to that of 0.5 s1 for pNP-(GlcNAc)3. While
this is lower than 4MU-(GlcNAc)3 with a kcat of 15.7 s1 and a Km
of 53 lM [16], turnover is in line with chitin pseudo substrates
and demonstrates the differential effects of aglycones on CHIT1
reaction rates.
LacNAc-TMR which contains an N-acetyl group (acetamido) at
the reducing end but lacks an N-acetyl group at the non-reducing
end (Fig. 1 and Supplementary Fig. 1) was also a substrate though
its turnover was considerably slower (0.003 s1). The catalytic
reaction for family 18 chitinase such as CHIT1 is believed to occur
with substrate assisted catalysis with attack of the N-acetyl group
on C-1 of substrate to cleave the glycosidic bond and generate an
oxazoline intermediate. LacNAc-TMR contains the requisite N-
acetyl for substrate assisted catalysis. The greater turnover of Lacd-
iNAc is attributed to additional binding interactions since it con-
tains two N-acetyl groups. Interactions with the N-acetyl group
Fig. 5. UPLC–Mass Spectrometry analysis of potential oligosaccharide substrates, before (A) and after the reaction with CHIT1 (B).
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allosamidine inhibitor complexes [17,18]. The -2 subsite corre-
sponds to the non-reducing end of LacNAc-TMR thus accounting
for its lower reactivity compared to LacdiNAc-TMR which has an
N-acetyl substituent in the -2 subsite. The isomeric Type 1-TMR
(Galb1,3GlcNAc) was not a substrate, as expected for chitinases
that hydrolyze b1,4 linked chitin.
There are limited sources of oligosaccharides terminating in
LacNAc or LacdiNAc. We found that disaccharide units were
sequentially hydrolyzed from LacNAcb1-60LacNAc-TMR. While oli-
gosaccharides with b1,4 linkages are expected to be substrates for
CHIT1, the hydrolysis of LacNAcb1-60LacNAc-TMR is attributed to
the ﬂexibility of the b1,6 linkage. There was minimal activity on
the extended Core 2 substrate and no activity with LacNAcMan.
Thus terminal LacNAc or LacdiNAc structures linked b1,4 or b1,6
in oligosaccharides, glycoproteins or glycolipids are potential sub-
strates for CHIT1. The altered glycosylation upon hydrolysis by
CHIT1 might be associated with pathologies.
It has been suggested that CHIT1 has a role in the defense to-
wards chitin containing pathogens [19] however elevated expres-
sion of CHIT1 has also been associated with a range of human
diseases that have no obvious connection to chitin containing
pathogens. These include Gaucher type I disease [20], Alzheimer’s
disease [21–23], type B Niemann-Pick disease [24], sarcoidosis
[25,26], atherosclerosis [27], multiple sclerosis [28,29] and sclero-
derma-associated lung disease where CHIT1 has even beenproposed as a potential therapeutic target [30]. The speciﬁc effects
of the CHIT1 in these diseases are not known.
Our results suggest that CHIT1 might adopt an activity towards
GlcNAc containing substrates present in the human host, as per-
haps glycan substrates found in association with the surface or
cytosol of epithelial cells and/or macrophages. This study provides
the ﬁrst demonstration that mammalian like glycans may provide
potential substrates for CHIT1. It should be considered that there
may not be a common target for the actions of CHIT1 in relation
to the diseases described above but rather that distinct targets
might be relevant under different circumstances. It can be per-
ceived, however, that glycans that contain either a LacNAc or Lacd-
iNAc motif might be a part of the target with the concomitant
alterations in glycosylation contributing to the pathogenic re-
sponse. It is of considerable interest that chitinases produced by
bacterial pathogens such as Legionella pneumophila, Listeria mono-
cytogenes and Salmonella may act as virulence factors by targeting
similar substrates [31].
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